Aging interventions moved closer to clinical translation with an aging endpoint shift. A Proteomic Aging Clock entered the clinic in a landmark Phase 2a geroprotection trial, positioning proteomics as a faster-to-track alternative to multi-year clinical aging endpoints. In parallel, a framework for epigenetic age testing faced expert backlash over reliability, privacy and ageism concerns, highlighting the compliance and ethics friction that can slow adoption even when tests are technically feasible. Finally, a review proposed a new “Oxygenaging” framework tying the body’s oxygen cascade to the biology of growing old, adding mechanistic targets for future gerotherapeutics. Together, the field is racing to build endpoints that are credible enough for regulators and acceptable enough for patients, while refining biomarkers that can survive scrutiny.